MAGE-A1 peptide–HLA-C*07:02 complex

The MAGE-A1 peptide–HLA-C*07:02 complex consists of an antigenic peptide derived from the MAGE-A1 protein, a cancer/testis antigen widely expressed in various tumors, presented by the human leukocyte antigen HLA-C*07:02, an MHC class I molecule. This complex is recognized by the T cell receptor (TCR) on cytotoxic T lymphocytes, making it an important target in anti-cancer immunotherapies including engineered TCR and CAR T cell approaches. It also serves as a diagnostic reagent in the form of peptide–MHC multimers to identify and quantify antigen-specific T cells in patients. The specificity and safety profile depend on the precise peptide sequence bound to HLA-C*07:02 and careful exclusion of cross-reactivity to minimize risks in clinical settings.

Other names

MAGE-A1/HLA-C*07:02 complexMAGE-A1 epitope–HLA-C*07:02pMHC (peptide–major histocompatibility complex) containing MAGE-A1 and HLA-C*07:02

Target recognition: TCRs or CARs bind the MAGE-A1 peptide–HLA-C*07:02 complex, activating cytotoxic T cell response leading to tumor cell lysis. Diagnostic: Peptide–HLA multimers used to stain or isolate antigen-specific T cells.